Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: Experience from an immunotherapy unit of rheumatology

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1307-1314

  Lequerré, Thierry ^a   Vittecoq, Olivier ^a   Klemmer, Nathalie ^a   Goëb, Vincent ^a   Pouplin, Sophie ^a   Menard, Jean Francois ^a   Daragon, Alain ^a   Mejjad, Othmane ^a   Le Loët, Xavier ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Infliximab; Infusion rate; Infusion reactions; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; CETIRIZINE; DEXCHLORPHENIRAMINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NICARDIPINE; OXYGEN; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; EVALUATION RESEARCH; FEMALE; FEVER; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SHIVERING; SPONDYLITIS; SPONDYLOARTHRITIS; TACHYCARDIA; THROAT DISEASE; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG TOXICITY; HUMANS; INFUSIONS, INTRAVENOUS; PRACTICE GUIDELINES; RHEUMATOLOGY; SPONDYLARTHRITIS;

EID: 33745779224     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
2. Maini R, St. Clair ET, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
3. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment and infusion number. J Rheumatol 2004;31:1912-7.
4. Buch MH, Lindsay S, Bryer D, Fairclough A, Rees-Evans B, Emery P. Incidence of infusion related reactions in patients receiving infliximab: recommendations for administration recommendations. Ann Rheum Dis 2004;63:285 [abstract].
5. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthritis Study Group preliminary criteria for the classification of spondylarthritis. Arthritis Rheum 1991;34:1218-27.
8. Braun J, Pham T, Sieper J, et al, for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
9. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
10. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:1647-9.
11. Farell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterol 2003;124:917-24.
12. Wagner CL, St. Clair EW, Han C, et al. Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study [abstract]. Arthritis Rheum 2002;Suppl 46:s132.
13. Van Vollenhoven RF, Gullström E, Klareskog L. Feasibility of 1 hour infliximab infusions [letter]. Ann Rheum Dis 2005;64:654.